PCSK9 and COVID-19: Barkas et al. suggest that proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, through their immunomodulatory properties, may reduce the risk of serious complications of COVID-19, such as acute respiratory distress syndrome and cytokine release syndrome [105].